OliX

팝업닫기

Refusal of Unauthorized Collection of E-mail Addresses

We do not allow the unauthorized collection of e-mail addresses listed on our website.Persons engaging in unauthorized collection with e-mail address collection programs or other technical devices will be subject to criminal prosecution in accordance with the Act on Information & Communications Network Utilization and Information Protection.

Contact Us

form mail list
Name *
Tel *	- -
E-mail *	@
Subject *
Contents
File1
File2
Spam Check*	* 왼쪽의 자동등록방지 코드를 입력하세요.

Consent to Collect and Use Personal Information

I agree to the use of personal information collected from myself or other legitimate sources.

Information collected : Name, Phone number, E-mail, Message
Purpose of collection and use : conducting certain services or activities including but not limited to replying to inquiries and maintaining business records.
Period of retention and use : Personal information is to be discarded after the purpose of collection and use has been achieved.

- Personal Information shall be discarded without delay once the purpose of collection and use has been achieved; provided however that, if an obligation to retain such information exists under applicable law(s), the information shall be retained for a period of time as required by such law(s).
- Even prior to the purpose of use and collection being achieved, personal information may be discarded upon request via email sent to olixpharma@olixpharma.com. Please note, however, that your use of the services herein may be limited.

※ You have the right not to consent to the collection and use of your personal information, in which event your use of the services may be limited.

I agree to the terms and conditions.

Platform Technology

RNAi platform development

Lead compound discovery

Pulmonology / Neurology

Pharmacological research on OliX RNAi compounds for respiratory and neurological diseases

Ophthalmology

Pharmacological research on OliX RNAi compounds for ocular diseases

Animal Research

Testing efficacy of oligonucleotide therapeutics using animal models

Analytics

Develop analytical methods for therapeutic candidates to determine purity and stability in support of nonclinical and clinical studies

PK/TK

Develop bioanalytical methods to quantitate therapeutic candidates in biological matrices for pharmacokinetic and toxicokinetic (PK/TK) studies

CMC

Manage manufacturing, analytics and quality of therapeutic candidates

Toxicology

Conduct safety evaluation and toxicokinetic assessment of therapeutic candidates through nonclinical studies

Clinical

Establish clinical development plans for therapeutic candidates and conduct clinical studies

Management

Business Management

Purchasing

General Affairs

Facility Management

Contingency Planning

Planning

Budget/Performance Management

Mid to Long-term Business Goals/Strategy Planning

Accounting & Finance

Make official announcements about business contents, financial condition, business performance etc.

Stabilize Internal Accounting Control System

IT

IT Infrastructure Management

IT Helpdesk

Human Resources

HR Policy/System Establishment, Organization/Job Design

Recruitment/HR Management

Performance Management, Employee Welfare

HR Development

Legal Affairs

Prevent, respond, handle legal disputes

Provide risk management and compliance support

Develop IP strategies for core technologies

Quality Assurance(QA)

Verify pharmaceutical R&D processes and results

Ensure product to meet the established quality standards

Business Development

Develop/Maintain Client Relationships

Execute Licensing Agreements

New Business/Strategy Planning

Communications

Provide investment information in a timely manner to increase company value

Promote management activities and establish internal/external communication strategies

Create positive corporate culture through various in-house activities and employee education

Home
IR

IR

Stock Information

Stock Information

2023/06/04 15:21:22 (장마감)

· Stock Information

- A226950
  OliX
- Now 20,250
- Change ▲610(3.11%)
- Volume 34,619
- Value 694,299,890

Current	19,900	Upper Limit		25,500
High	20,250	Lower Limit		13,750
Low	19,810	Par Value		500
PER	0.00	52 week	High	29,250
Listed Stocks	13,734,160	52 week	Low	16,750

· Price

Ask Size	A&B	Bid Size
1,417	20,450
524	20,400
817	20,350
1,012	20,300
510	20,250
	20,200	214
	20,150	141
	20,100	37
	20,050	458
	20,000	42
4,280	Total	892

· Hourly Prices

Time	Close(￦)	Change	Ask Price	Bid Price	Volume
15:30:00	20,250	610	20,250	20,200	471
15:19:50	20,250	610	20,250	20,200	15
15:19:40	20,250	610	20,250	20,200	26
15:19:30	20,250	610	20,250	20,200	5
15:19:10	20,250	610	20,250	20,200	100
15:19:00	20,200	560	20,250	20,200	25
15:18:40	20,200	560	20,250	20,200	20
15:16:40	20,200	560	20,250	20,200	1
15:16:10	20,200	560	20,250	20,200	20
15:15:50	20,200	560	20,250	20,200	30

· Daily Prices

Date	Close(￦)	Change	Current	High	Low	Volume	Value
23/06/02	20,250	610	19,900	20,250	19,810	34,619	694,299,890
23/06/01	19,640	410	19,410	19,890	19,410	38,742	764,607,660
23/05/31	19,230	10	19,220	19,750	19,050	37,509	725,740,240
23/05/30	19,220	520	19,740	19,800	19,190	51,864	999,820,400
23/05/26	19,740	80	19,940	19,940	19,550	31,203	614,189,410
23/05/25	19,820	150	19,970	20,050	19,740	25,181	499,874,920
23/05/24	19,970	330	20,600	20,600	19,970	20,148	404,359,440
23/05/23	20,300	100	20,100	20,550	20,100	18,394	373,607,000
23/05/22	20,400	410	19,990	20,750	19,850	56,197	1,145,144,820
23/05/19	19,990	130	19,980	20,050	19,550	27,423	542,842,410